A novel hydroxysuberamide derivative potentiates MG132-mediated anticancer activity against human hormone refractory prostate cancers - The role of histone deacetylase and endoplasmic reticulum stress

Prostate

Volumn 73, Issue 12, 2013, Pages 1270-1280

  Chen, Yi Cheng ^a   Huang, Wei Jan ^b   Hsu, Jui Ling ^a   Yu, Chia Chun ^a   Wang, Wei Ting ^a   Guh, Jih Hwa ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

DNA repair; GADD153; HDAC inhibitor; intrinsic and extrinsic apoptosis pathways; proteasome inhibitor

Indexed keywords

ANTINEOPLASTIC AGENT; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CAMPTOTHECIN; CASPASE 3; CASPASE 8; CASPASE 9; CYCLIN A; CYCLIN B1; CYCLIN D1; CYCLIN E; DOXORUBICIN; ETOPOSIDE; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; HISTONE DEACETYLASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 4; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE INHIBITOR; HISTONE H3; KU ANTIGEN; PACLITAXEL; PROTEIN BCL 2; PROTEIN P21; SMALL INTERFERING RNA; SULFORHODAMINE B; UNCLASSIFIED DRUG; VINCRISTINE; VORINOSTAT; WJ 25591;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BINDING AFFINITY; CASTRATION RESISTANT PROSTATE CANCER; CELL CYCLE PROGRESSION; CELL PROLIFERATION; COMET ASSAY; CONTROLLED STUDY; DNA BINDING; DNA DAMAGE; DNA REPAIR; DNA REPLICATION; DNA SYNTHESIS; DOWN REGULATION; ENDOPLASMIC RETICULUM STRESS; FLOW CYTOMETRY; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; GENE SILENCING; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING;

DNA REPAIR; GADD153; HDAC INHIBITOR; INTRINSIC AND EXTRINSIC APOPTOSIS PATHWAYS; PROTEASOME INHIBITOR;

ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL LINE, TUMOR; DRUG SYNERGISM; ENDOPLASMIC RETICULUM STRESS; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; LEUPEPTINS; MALE; PROSTATIC NEOPLASMS; PROTEASOME INHIBITORS;

EID: 84881069615     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22641     Document Type: Article

References (44)

1. Marmorstein R,. Structure of histone deacetylases: Insights into substrate recognition and catalysis. Structure 2001; 9 (12): 1127-1133.
2. Johnstone RW, Licht JD,. Histone deacetylase inhibitors in cancer therapy: Is transcription the primary target ? Cancer Cell 2003; 4 (1): 13-18.
3. Shankar S, Srivastava RK,. Histone deacetylase inhibitors: Mechanisms and clinical significance in cancer: HDAC inhibitor-induced apoptosis. Adv Exp Med Biol 2008; 615: 261-298.
4. Strahl BD, Allis CD,. The language of covalent histone modifications. Nature 2000; 403 (6765): 41-45.
5. Kim HJ, Bae SC,. Histone deacetylase inhibitors: Molecular mechanisms of action and clinical trials as anti-cancer drugs. Am J Transl Res 2011; 3 (2): 166-179.
6. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK,. Histone deacetylases and cancer: Causes and therapies. Nat Rev Cancer 2001; 1 (3): 194-202.
7. Xu Q, Lu R, Zhu ZF, Lv JQ, Wang LJ, Zhang W, Hu JW, Meng J, Lin G, Yao Z,. Effects of tyroservatide on histone acetylation in lung carcinoma cells. Int J Cancer 2011; 128 (2): 460-472.
8. Wanczyk M, Roszczenko K, Marcinkiewicz K, Bojarczuk K, Kowara M, Winiarska M,. HDACi-going through the mechanisms. Front Biosci 2011; 16: 340-359.
9. Lawless MW, O'Byrne KJ, Gray SG,. Targeting oxidative stress in cancer. Expert Opin Ther Targets 2010; 14 (11): 1225-1245.
10. Grant S, Easley C, Kirkpatrick P,. Vorinostat. Nat Rev Drug Discov 2007; 6 (1): 21-22.
11. Molife LR, Attard G, Fong PC, Karavasilis V, Reid AH, Patterson S, Riggs CEJr, Higano C, Stadler WM, McCulloch W, Dearnaley D, Parker C, de Bono JS,. Phase II, two-stage, singlearm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castrationresistant prostate cancer (CRPC). Ann Oncol 2010; 21 (1): 109-113.
12. Stadler WM, Margolin K, Ferber S, McCulloch W, Thompson JA,. A phase II study of depsipeptide in refractory metastatic renal cell cancer. Clin Genitourin Cancer 2006; 5 (1): 57-60.
13. Schrump DS, Fischette MR, Nguyen DM, Zhao M, Li X, Kunst TF, Hancox A, Hong JA, Chen GA, Kruchin E, Wright JJ, Rosing DR, Sparreboom A, Figg WD, Steinberg SM,. Clinical and molecular responses in lung cancer patients receiving Romidepsin. Clin Cancer Res 2008; 14 (1): 188-198.
14. Kumagai T, Wakimoto N, Yin D, Gery S, Kawamata N, Takai N, Komatsu N, Chumakov A, Imai Y, Koeffler HP,. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells. Int J Cancer 2007; 121 (3): 656-665.
15. Komatsu N, Kawamata N, Takeuchi S, Yin D, Chien W, Miller CW, Koeffler HP,. SAHA, a HDAC inhibitor, has profound anti-growth activity against non-small cell lung cancer cells. Oncol Rep 2006; 15 (1): 187-191.
16. Kang MR, Kang JS, Han SB, Kim JH, Kim DM, Lee K, Lee CW, Lee KH, Lee CH, Han G, Kang JS, Kim HM, Park SK,. A novel delta-lactam-based histone deacetylase inhibitor, KBH-A42, induces cell cycle arrest and apoptosis in colon cancer cells. Biochem Pharmacol 2009; 78 (5): 486-494.
17. Soria G, Speroni J, Podhajcer OL, Prives C, Gottifredi V,. p21 differentially regulates DNA replication and DNA-repair-associated processes after UV irradiation. J Cell Sci 2008; 121 (Pt 19): 3271-3282.
18. Shi YK, Li ZH, Han XQ, Yi JH, Wang ZH, Hou JL, Feng CR, Fang QH, Wang HH, Zhang PF, Wang FS, Shen J, Wang P,. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer. Cancer Chemother Pharmacol 2010; 66 (6): 1131-1140.
19. Miller CP, Ban K, Dujka ME, McConkey DJ, Munsell M, Palladino M, Chandra J,. NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells. Blood 2007; 110 (1): 267-277.
20. Shiozawa K, Nakanishi T, Tan M, Fang HB, Wang WC, Edelman MJ, Carlton D, Gojo I, Sausville EA, Ross DD,. Preclinical studies of vorinostat (suberoylanilide hydroxamic acid) combined with cytosine arabinoside and etoposide for treatment of acute leukemias. Clin Cancer Res 2009; 15 (5): 1698-1707.
21. Zhao L, Wientjes MG, Au JL,. Evaluation of combination chemotherapy: Integration of nonlinear regression, curve shift, isobologram, and combination index analyses. Clin Cancer Res 2004; 10 (23): 7994-8004.
22. Halkidou K, Gaughan L, Cook S, Leung HY, Neal DE, Robson CN,. Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate 2004; 59 (2): 177-189.
23. Wilson AJ, Byun DS, Popova N, Murray LB, L'Italien K, Sowa Y, Arango D, Velcich A, Augenlicht LH, Mariadason JM,. Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. J Biol Chem 2006; 281 (19): 13548-13558.
24. Choi JH, Kwon HJ, Yoon BI, Kim JH, Han SU, Joo HJ, Kim DY,. Expression profile of histone deacetylase 1 in gastric cancer tissues. Jpn J Cancer Res 2001; 92 (12): 1300-1304.
25. Song J, Noh JH, Lee JH, Eun JW, Ahn YM, Kim SY, Lee SH, Park WS, Yoo NJ, Lee JY, Nam SW,. Increased expression of histone deacetylase 2 is found in human gastric cancer. APMIS 2005; 113 (4): 264-268.
26. Lagger G, O'Carroll D, Rembold M, Khier H, Tischler J, Weitzer G, Schuettengruber B, Hauser C, Brunmeir R, Jenuwein T, Seiser C,. Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression. EMBO J 2002; 21 (11): 2672-2681.
27. Witt O, Deubzer HE, Milde T, Oehme I,. HDAC family: What are the cancer relevant targets ? Cancer Lett 2009; 277 (1): 8-21.
28. Zhao X, Sternsdorf T, Bolger TA, Evans RM, Yao TP,. Regulation of MEF2 by histone deacetylase 4- and SIRT1 deacetylase-mediated lysine modifications. Mol Cell Biol 2005; 25 (19): 8456-8464.
29. Backs J, Worst BC, Lehmann LH, Patrick DM, Jebessa Z, Kreusser MM, Sun Q, Chen L, Heft C, Katus HA, Olson EN,. Selective repression of MEF2 activity by PKA-dependent proteolysis of HDAC4. J Cell Biol 2011; 195 (3): 403-415.
30. Bai X, Wu L, Liang T, Liu Z, Li J, Li D, Xie H, Yin S, Yu J, Lin Q, Zheng S,. Overexpression of myocyte enhancer factor 2 and histone hyperacetylation in hepatocellular carcinoma. J Cancer Res Clin Oncol 2008; 134 (1): 83-91.
31. Xu WS, Parmigiani RB, Marks PA,. Histone deacetylase inhibitors: Molecular mechanisms of action. Oncogene 2007; 26 (37): 5541-5552.
32. Deavall DG, Martin EA, Horner JM, Roberts R,. Drug-induced oxidative stress and toxicity. J Toxicol 2012; 2012: 645460.
33. Dulic̈ V, Kaufmann WK, Wilson SJ, Tlsty TD, Lees E, Harper JW, Elledge SJ, Reed SI,. p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 1994; 76 (6): 1013-1023.
34. Stark GR, Taylor WR,. Control of the G2/M transition. Mol Biotechnol 2006; 32 (3): 227-248.
35. Chipuk JE, Moldoveanu T, Llambi F, Parsons MJ, Green DR,. The BCL-2 family reunion. Mol Cell 2010; 37 (3): 299-310.
36. DiPaola RS, Aisner J,. Overcoming bcl-2- and p53-mediated resistance in prostate cancer. Semin Oncol 1999; 26 (1 Suppl. 2): 112-116.
37. Castilla C, Congregado B, Chinchón D, Torrubia FJ, Japón MA, Sáez C,. Bcl-xL is overexpressed in hormone-resistant prostate cancer and promotes survival of LNCaP cells via interaction with proapoptotic Bak. Endocrinology 2006; 147 (10): 4960-4967.
38. Kim HJ, Kang SK, Mun JY, Chun YJ, Choi KH, Kim MY,. Involvement of Akt in mitochondria-dependent apoptosis induced by a cdc25 phosphatase inhibitor naphthoquinone analog. FEBS Lett 2003; 555 (2): 217-222.
39. Healy SJ, Gorman AM, Mousavi-Shafaei P, Gupta S, Samali A,. Targeting the endoplasmic reticulum-stress response as an anticancer strategy. Eur J Pharmacol 2009; 625 (1-3): 234-246.
40. Cho HY, Thomas S, Golden EB, Gaffney KJ, Hofman FM, Chen TC, Louie SG, Petasis NA, Schönthal AH,. Enhanced killing of chemo-resistant breast cancer cells via controlled aggravation of ER stress. Cancer Lett 2009; 282 (1): 87-97.
41. Zinszner H, Kuroda M, Wang X, Batchvarova N, Lightfoot RT, Remotti H, Stevens JL, Ron D,. CHOP is implicated in programmed cell death in response to impaired function of the endoplasmic reticulum. Genes Dev 1998; 12 (7): 982-995.
42. Li J, Lee B, Lee AS,. Endoplasmic reticulum stress-induced apoptosis: Multiple pathways and activation of p53-up-regulated modulator of apoptosis (PUMA) and NOXA by p53. J Biol Chem 2006; 281 (11): 7260-7270.
43. Nawrocki ST, Carew JS, Maclean KH, Courage JF, Huang P, Houghton JA, Cleveland JL, Giles FJ, McConkey DJ,. Myc regulates aggresome formation, the induction of Noxa, and apoptosis in response to the combination of bortezomib and SAHA. Blood 2008; 112 (7): 2917-2926.
44. Duchen MR,. Mitochondria and calcium: From cell signaling to cell death. J Physiol 2000; 529: 57-68.